Public Health Warning Against Unregistered Fat Burner HCA 500mg Capsule Containing Both Amphetamine and Sibutramine
The Food and Drug Administration (FDA) tested Fat Burner HCA 500 mg, an unregistered slimming product in capsule form, and the laboratory test report showed the presence of both Amphetamine and Sibutramine. The product label showed that the product is manufactured by America Bysilver Pharmaceutical Co., Ltd.
The capsules packaged in a box of foil strips were collected by the FDA Inspectorate at the Bureau of Customs (BOC) in South Harbor, Port Area, Manila.
The public is hereby warned against buying and using Fat Burner HCA 500mg capsule in the market or through online. The tested samples came from a batch which were manufactured in 2013 and will expire in 2018, and there is a chance that the same batch of the product is being offered for sale or use to unsuspecting buyers.
On 8 January 2014, the FDA warned the public against using 26 slimming products which contained amphetamine, sibutramine and steroids. Amphetamine causes irregular heartbeat, confusion, urine retention and painful urination, hyperthermia, hyperreflexia, muscle pain, severe agitation, rapid breathing, and tremor. Large overdose may produce symptoms such as psychosis, anuria, cardiogenic shock, cerebral hemorrhage, circulatory collapse, extreme fever, pulmonary hypertension, renal failure, rapid muscle breakdown, serotonin syndrome, and stereotypy. Fatal amphetamine poisoning usually involves convulsion and coma. On the other hand, Sibutramine has been shown to increase the risk of serious heart events, including non-fatal heart attack or non-fatal stroke and death, in 16% of the group of patients which was given sibutramine compared with the placebo group. FDA Advisory 2014-002
All consumers are advised to use only FDA-approved slimming pills or anti-obesity drugs under the supervision of doctors. All FDA inspectors are hereby ordered to seize unregistered slimming products or those containing amphetamine, sibutramine or steroids from all outlets or establishments where they are found or offered for sale or use. The FDA appeals to the BOC to be more vigilant in guarding the Philippine borders from the entry of unregistered or illegal health products.